Postprandial levels of GLP-1, GIP and glucagon after 2 years of weight loss with a Paleolithic diet: a randomised controlled trial in healthy obese women

被引:29
|
作者
Otten, Julia [1 ]
Ryberg, Mats [1 ]
Mellberg, Caroline [1 ]
Andersson, Tomas [1 ]
Chorell, Elin [1 ]
Lindahl, Bernt [1 ]
Larsson, Christel [2 ]
Holst, Jens Juul [3 ,4 ]
Olsson, Tommy [1 ]
机构
[1] Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden
[2] Univ Gothenburg, Dept Food & Nutr & Sport Sci, Gothenburg, Sweden
[3] Univ Copenhagen, NNF Ctr Basal Metab Res, Copenhagen, Denmark
[4] Univ Copenhagen, Dept Biomed Sci, Copenhagen, Denmark
基金
瑞典研究理事会;
关键词
GASTRIC-INHIBITORY POLYPEPTIDE; PEPTIDE-1; RELEASE; INCRETIN HORMONE; ORAL GLUCOSE; RISK-FACTORS; INSULIN; FAT; MAINTENANCE; SECRETION; METABOLISM;
D O I
10.1530/EJE-19-0082
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To investigate how weight loss by different diets impacts postprandial levels of glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon. Methods: In this single-centre, parallel group 2-year trial, 70 healthy postmenopausal obese women were randomised to the Paleolithic diet or a healthy control diet based on Nordic Nutrition Recommendations. Both diets were without calorie restriction. The primary outcome was the change in fat mass. Here, secondary analyses on GLP-1, GIP and glucagon measured during an OGTT are described. Results: In the Paleolithic diet group, mean weight loss compared to baseline was 11% at 6 months and 10% at 24 months. In the control diet group, mean weight loss was 6% after 6 and 24 months (P = 0.0001 and P = 0.049 for the comparison between groups at 6 and 24 months respectively). Compared to baseline, the mean incremental area under the curve (iAUC) for GLP-1 increased by 34 and 45% after 6 and 24 months in the Paleolithic diet group and increased by 59% after 24 months in the control diet group. The mean iAUC for GIP increased only in the Paleolithic diet group. The area under the curve (AUC) for glucagon increased during the first 6 months in both groups. The fasting glucagon increase correlated with the beta-hydroxybutyrate increase. Conclusions: Weight loss caused an increase in postprandial GLP-1 levels and a further rise occurred during weight maintenance. Postprandial GIP levels increased only after the Paleolithic diet. Reduced postprandial glucagon suppression may be caused by a catabolic state.
引用
收藏
页码:417 / 427
页数:11
相关论文
共 14 条
  • [1] Increased Postprandial GIP and Glucagon Responses, But Unaltered GLP-1 Response after Intervention with Steroid Hormone, Relative Physical Inactivity, And High-Calorie Diet in Healthy Subjects
    Hansen, Katrine B.
    Vilsboll, Tina
    Bagger, Jonatan I.
    Holst, Jens J.
    Knop, Filip K.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (02) : 447 - 453
  • [2] Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet
    Jensen, Simon Birk Kjaer
    Lundgren, Julie Rehne
    Janus, Charlotte
    Juhl, Christian Rimer
    Olsen, Lisa Moller
    Rosenkilde, Mads
    Holst, Jens Juul
    Stallknecht, Bente Merete
    Madsbad, Sten
    Torekov, Signe Sorensen
    BMJ OPEN, 2019, 9 (11):
  • [3] EFFECT OF SITAGLIPTIN ON POSTPRANDIAL GLUCAGON AND GLP-1 LEVELS IN PATIENTS WITH TYPE 1 DIABETES: INVESTIGATOR-INITIATED, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL
    Garg, Satish K.
    Moser, Emily G.
    Bode, Bruce W.
    Klaff, Leslie J.
    Hiatt, William R.
    Beatson, Christie
    Snell-Bergeon, Janet K.
    ENDOCRINE PRACTICE, 2013, 19 (01) : 19 - 28
  • [4] Why does GLP-1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP-1 agonist alone in obese adults without type 2 diabetes?
    Jiang, Yuchen
    Zhu, Huijuan
    Gong, Fengying
    DIABETES OBESITY & METABOLISM, 2025, 27 (03) : 1079 - 1095
  • [5] Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
    Rosenstock, Julio
    Frias, Juan
    Jastreboff, Ania M.
    Du, Yu
    Lou, Jitong
    Gurbuz, Sirel
    Thomas, Melissa K.
    Hartman, Mark L.
    Haupt, Axel
    Milicevic, Zvonko
    Coskun, Tamer
    LANCET, 2023, 402 (10401) : 529 - 544
  • [6] Intra-pancreatic fat is associated with high circulating glucagon and GLP-1 concentrations following whey protein ingestion in overweight women with impaired fasting glucose: A randomised controlled trial
    Lim, Jia Jiet
    Sequeira-Bisson, Ivana R.
    Yip, Wilson C. Y.
    Lu, Louise W.
    Miles-Chan, Jennifer L.
    Poppitt, Sally D.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 207
  • [7] Effects of milk protein concentrate supplementation on metabolic parameters, adipocytokines and body composition in obese women under weight-loss diet: study protocol for a randomised controlled trial
    Haidari, Fatemeh
    Elahikhah, Mahsa
    Islam, Sheikh Mohammed Shariful
    Mohammadshahi, Majid
    Shahbazian, Hajieh
    Aghamohammadi, Vahideh
    BMJ OPEN, 2022, 12 (10):
  • [8] MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
    Ambery, Philip
    Parker, Victoria E.
    Stumvoll, Michael
    Posch, Maximilian G.
    Heise, Tim
    Plum-Moerschel, Leona
    Tsai, Lan-Feng
    Robertson, Darren
    Jain, Meena
    Petrone, Marcella
    Rondinone, Cristina
    Hirshberg, Boaz
    Jermutus, Lutz
    LANCET, 2018, 391 (10140) : 2607 - 2618
  • [9] The Effect of Antrum Size on Weight Loss, Glucagon-Like Peptide-1 (GLP-1) Levels, and Glycemic Control Following Laparoscopic Sleeve Gastrectomy in Adolescents with Obesity and Type 2 Diabetes
    Shehata, Mohamed A.
    Elhaddad, Ahmed
    El-Attar, Ashraf A.
    Shehata, Sherif M.
    OBESITY SURGERY, 2021, 31 (10) : 4376 - 4385
  • [10] Co-ingestion of NUTRALYS® pea protein and a high-carbohydrate beverage influences the glycaemic, insulinaemic, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) responses: preliminary results of a randomised controlled trial
    Pariyarath Sangeetha Thondre
    Ifunanya Achebe
    Alistair Sampson
    Tyler Maher
    Laetitia Guérin-Deremaux
    Catherine Lefranc-Millot
    Elisabeth Ahlström
    Helen Lightowler
    European Journal of Nutrition, 2021, 60 : 3085 - 3093